Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 11.66
-0.85 %
$ 1.88 B
Market Cap
-58.3
P/E
1. INTRINSIC VALUE
Balance Sheet
Certara, Inc.
| Current Assets | 340 M |
| Cash & Short-Term Investments | 235 M |
| Receivables | 93.3 M |
| Other Current Assets | 12 M |
| Non-Current Assets | 1.22 B |
| Long-Term Investments | 1.15 M |
| PP&E | 12.3 M |
| Other Non-Current Assets | 1.21 B |
| Current Liabilities | 130 M |
| Accounts Payable | 5.17 M |
| Short-Term Debt | 7.4 M |
| Other Current Liabilities | 117 M |
| Non-Current Liabilities | 386 M |
| Long-Term Debt | 295 M |
| Other Non-Current Liabilities | 91.1 M |
EFFICIENCY
Earnings Waterfall
Certara, Inc.
| Revenue | 354 M |
| Cost Of Revenue | 141 M |
| Gross Profit | 213 M |
| Operating Expenses | 254 M |
| Operating Income | -40.8 M |
| Other Expenses | 14.6 M |
| Net Income | -55.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Certara, Inc.
| Net Income | -55.4 M |
| Depreciation & Amortization | 56.1 M |
| Capital Expenditures | -15.3 M |
| Stock-Based Compensation | 28.3 M |
| Change in Working Capital | -4.72 M |
| Others | 75.7 M |
| Free Cash Flow | 67.4 M |
Wall Street Analysts Price Targets
Certara, Inc.
Wall Street analysts predict an average 1-year price target for CERT of $17 , with forecasts ranging from
a
low of
$13 to a high of $23 .
CERT Lowest Price Target
Wall Street Target
13 USD
11.49%
CERT Average Price Target
Wall Street Target
17 USD
45.80%
CERT Highest Price Target
Wall Street Target
23 USD
97.26%
4. DIVIDEND
ANALYSIS
CERT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Certara, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
638 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
550 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 months ago
Oct 07, 2024
|
Sell 59.7 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 5409
|
11.03 USD |
|
4 months ago
Sep 09, 2024
|
Sell 578 K
USD
|
Pedersen Leif E
PRESIDENT, CHIEF COMMERCAL OFF
|
- 51224
|
11.29 USD |
|
9 months ago
Apr 02, 2024
|
Sell 88.2 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 5264
|
16.76 USD |
|
9 months ago
Apr 02, 2024
|
Sell 11.5 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 649
|
17.72 USD |
|
9 months ago
Apr 02, 2024
|
Sell 50.7 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 3024
|
16.75 USD |
|
9 months ago
Apr 02, 2024
|
Sell 5.8 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 328
|
17.67 USD |
|
9 months ago
Apr 02, 2024
|
Sell 79.5 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 4740
|
16.77 USD |
|
9 months ago
Apr 02, 2024
|
Sell 7.5 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 422
|
17.77 USD |
|
9 months ago
Apr 01, 2024
|
Sell 54 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
18 USD |
|
10 months ago
Mar 04, 2024
|
Sell 54.8 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
18.28 USD |
|
10 months ago
Feb 20, 2024
|
Sell 90 K
USD
|
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
|
- 5000
|
18 USD |
|
11 months ago
Feb 12, 2024
|
Sell 108 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 6000
|
18 USD |
|
1 year ago
Dec 26, 2023
|
Sell 108 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 6000
|
18 USD |
|
1 year ago
Sep 11, 2023
|
Sell 748 K
USD
|
Pedersen Leif E
PRESIDENT, CHIEF COMMERCAL OFF
|
- 51224
|
14.6 USD |
|
1 year ago
Aug 22, 2023
|
Bought
76 K USD
|
BROSHY ERAN
Director
|
+ 4807
|
15.8 USD |
|
1 year ago
Aug 21, 2023
|
Bought
3.11 K USD
|
BROSHY ERAN
Director
|
+ 193
|
16.1 USD |
|
1 year ago
Jun 05, 2023
|
Sell 412 K
USD
|
SMITH PATRICK F
PRESIDENT, INTEGRATED DRUG DEV
|
- 19104
|
21.55 USD |
|
1 year ago
May 11, 2023
|
Sell 104 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
20.82 USD |
|
1 year ago
Apr 14, 2023
|
Sell 118 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
23.66 USD |
|
1 year ago
Mar 06, 2023
|
Sell 214 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 10000
|
21.45 USD |
|
1 year ago
Feb 02, 2023
|
Sell 300 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 15000
|
20 USD |
|
2 years ago
Dec 08, 2022
|
Sell 449 M
USD
|
EQT Avatar Parent L.P.
Director
|
- 29954521
|
15 USD |
|
2 years ago
Nov 22, 2022
|
Sell 797 K
USD
|
Pedersen Leif E
director: PRESIDENT, SOFTWARE
|
- 51223
|
15.55 USD |
|
2 years ago
Nov 14, 2022
|
Sell 64.2 K
USD
|
SLAINE MASON P
Director
|
- 4207
|
15.27 USD |
|
2 years ago
Nov 15, 2022
|
Sell 3.83 M
USD
|
SLAINE MASON P
Director
|
- 245793
|
15.57 USD |
|
2 years ago
Nov 14, 2022
|
Sell 178 K
USD
|
WALSH MATTHEW M
Director
|
- 12059
|
14.74 USD |
|
2 years ago
Nov 09, 2022
|
Sell 32.2 K
USD
|
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
|
- 2387
|
13.48 USD |
|
2 years ago
Aug 19, 2022
|
Bought
326 K USD
|
McLean Stephen M.
director:
|
+ 20000
|
16.32 USD |
|
2 years ago
Aug 17, 2022
|
Bought
416 K USD
|
Schemick Michael Andrew
director: CHIEF FINANCIAL OFFICER
|
+ 25000
|
16.64 USD |
|
2 years ago
Aug 16, 2022
|
Sell 177 K
USD
|
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
|
- 10000
|
17.71 USD |
|
2 years ago
Aug 16, 2022
|
Sell 104 M
USD
|
EQT Fund Management S.a r.l.
director:
|
- 6004418
|
17.38 USD |
|
2 years ago
Aug 16, 2022
|
Sell 3.17 M
USD
|
SLAINE MASON P
director:
|
- 182475
|
17.38 USD |
|
2 years ago
Jun 08, 2022
|
Sell 192 K
USD
|
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
|
- 10000
|
19.16 USD |
|
2 years ago
Jun 02, 2022
|
Sell 1.96 M
USD
|
SLAINE MASON P
director:
|
- 100000
|
19.59 USD |
|
2 years ago
May 31, 2022
|
Sell 28.5 M
USD
|
EQT Fund Management S.a r.l.
director:
|
- 1500000
|
19 USD |
|
2 years ago
Apr 01, 2022
|
Sell 74.7 K
USD
|
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
|
- 3352
|
22.29 USD |
|
2 years ago
Mar 16, 2022
|
Sell 60 K
USD
|
Traynor Richard M.
director: SVP AND GENERAL COUNSEL
|
- 3000
|
20 USD |
|
2 years ago
Mar 16, 2022
|
Sell 2.53 M
USD
|
SLAINE MASON P
director:
|
- 125000
|
20.25 USD |
|
2 years ago
Mar 16, 2022
|
Sell 1.26 M
USD
|
Feehery William F
director: CHIEF EXECUTIVE OFFICER
|
- 62485
|
20.17 USD |
|
2 years ago
Mar 11, 2022
|
Sell 558 K
USD
|
Feehery William F
director: CHIEF EXECUTIVE OFFICER
|
- 27515
|
20.29 USD |
|
2 years ago
Feb 18, 2022
|
Sell 1.64 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 70294
|
23.31 USD |
|
2 years ago
Feb 18, 2022
|
Sell 113 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 4706
|
23.93 USD |
|
2 years ago
Feb 17, 2022
|
Sell 1.27 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 53407
|
23.83 USD |
|
2 years ago
Feb 17, 2022
|
Sell 750 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 30075
|
24.93 USD |
|
2 years ago
Feb 17, 2022
|
Sell 166 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 6518
|
25.49 USD |
|
2 years ago
Feb 01, 2022
|
Sell 934 K
USD
|
SLAINE MASON P
Director
|
- 35199
|
26.53 USD |
|
2 years ago
Feb 01, 2022
|
Sell 397 K
USD
|
SLAINE MASON P
Director
|
- 14801
|
26.8 USD |
|
2 years ago
Jan 26, 2022
|
Sell 78 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
26.01 USD |
|
2 years ago
Jan 26, 2022
|
Sell 588 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 23804
|
24.72 USD |
|
2 years ago
Jan 26, 2022
|
Sell 1.31 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 51196
|
25.67 USD |
|
2 years ago
Jan 20, 2022
|
Sell 138 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 5000
|
27.5 USD |
|
3 years ago
Jan 18, 2022
|
Sell 137 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
27.44 USD |
|
3 years ago
Jan 03, 2022
|
Sell 1.15 M
USD
|
SLAINE MASON P
Director
|
- 40323
|
28.57 USD |
|
3 years ago
Jan 03, 2022
|
Sell 279 K
USD
|
SLAINE MASON P
Director
|
- 9677
|
28.88 USD |
|
3 years ago
Dec 27, 2021
|
Sell 87.9 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
29.3 USD |
|
3 years ago
Dec 23, 2021
|
Sell 733 K
USD
|
CASHMAN JAMES E III
Director
|
- 25111
|
29.2 USD |
|
3 years ago
Dec 22, 2021
|
Sell 577 K
USD
|
CASHMAN JAMES E III
Director
|
- 19889
|
29 USD |
|
3 years ago
Dec 22, 2021
|
Sell 2.14 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 75000
|
28.58 USD |
|
3 years ago
Dec 20, 2021
|
Sell 210 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 7500
|
28 USD |
|
3 years ago
Dec 17, 2021
|
Sell 131 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 5000
|
26.13 USD |
|
3 years ago
Dec 13, 2021
|
Sell 1.4 M
USD
|
SLAINE MASON P
Director
|
- 49900
|
28.05 USD |
|
3 years ago
Dec 13, 2021
|
Sell 2.86 K
USD
|
SLAINE MASON P
Director
|
- 100
|
28.55 USD |
|
3 years ago
Dec 07, 2021
|
Sell 418 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 15151
|
27.58 USD |
|
3 years ago
Dec 07, 2021
|
Sell 1.53 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 54849
|
27.82 USD |
|
3 years ago
Dec 03, 2021
|
Sell 1.73 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 66500
|
25.99 USD |
|
3 years ago
Dec 03, 2021
|
Sell 92.9 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 3500
|
26.54 USD |
|
3 years ago
Nov 24, 2021
|
Sell 3.62 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 127521
|
28.4 USD |
|
3 years ago
Nov 24, 2021
|
Sell 501 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 17479
|
28.66 USD |
|
3 years ago
Nov 22, 2021
|
Sell 11.2 M
USD
|
SLAINE MASON P
Director
|
- 376149
|
29.741 USD |
|
3 years ago
Nov 22, 2021
|
Sell 241 M
USD
|
EQT Avatar Parent L.P.
10 percent owner
|
- 8117655
|
29.741 USD |
|
3 years ago
Nov 19, 2021
|
Sell 2.12 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 70000
|
30.31 USD |
|
3 years ago
Nov 19, 2021
|
Sell 606 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 20000
|
30.3 USD |
|
3 years ago
Nov 15, 2021
|
Sell 2.49 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 65896
|
37.83 USD |
|
3 years ago
Nov 15, 2021
|
Sell 29.7 K
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 770
|
38.57 USD |
|
3 years ago
Nov 15, 2021
|
Sell 1.87 M
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 49300
|
37.84 USD |
|
3 years ago
Nov 15, 2021
|
Sell 27 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 700
|
38.56 USD |
|
3 years ago
Nov 15, 2021
|
Sell 117 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
38.96 USD |
|
3 years ago
Nov 15, 2021
|
Sell 556 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 14700
|
37.85 USD |
|
3 years ago
Nov 15, 2021
|
Sell 11.6 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 300
|
38.66 USD |
|
3 years ago
Nov 15, 2021
|
Sell 195 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
38.96 USD |
|
3 years ago
Nov 11, 2021
|
Sell 669 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 16962
|
39.43 USD |
|
3 years ago
Nov 11, 2021
|
Sell 184 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 4592
|
40.06 USD |
|
3 years ago
Oct 27, 2021
|
Sell 2.94 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 74800
|
39.24 USD |
|
3 years ago
Oct 27, 2021
|
Sell 7.95 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 200
|
39.76 USD |
|
3 years ago
Oct 26, 2021
|
Sell 120 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
39.95 USD |
|
3 years ago
Oct 26, 2021
|
Sell 120 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 3000
|
39.95 USD |
|
3 years ago
Oct 21, 2021
|
Sell 236 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 6116
|
38.6 USD |
|
3 years ago
Oct 20, 2021
|
Sell 489 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 12674
|
38.58 USD |
|
3 years ago
Oct 19, 2021
|
Sell 53.1 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 1434
|
37.05 USD |
|
3 years ago
Oct 19, 2021
|
Sell 690 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 18083
|
38.15 USD |
|
3 years ago
Oct 19, 2021
|
Sell 18.6 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 483
|
38.56 USD |
|
3 years ago
Oct 19, 2021
|
Sell 46.6 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 1210
|
38.55 USD |
|
3 years ago
Oct 18, 2021
|
Sell 2.26 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 62049
|
36.42 USD |
|
3 years ago
Oct 18, 2021
|
Sell 172 K
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 4618
|
37.33 USD |
|
3 years ago
Oct 15, 2021
|
Sell 187 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
37.38 USD |
|
3 years ago
Oct 15, 2021
|
Sell 187 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 5000
|
37.38 USD |
|
3 years ago
Oct 01, 2021
|
Sell 554 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 16587
|
33.39 USD |
|
3 years ago
Oct 01, 2021
|
Sell 94.7 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 2767
|
34.24 USD |
|
3 years ago
Sep 27, 2021
|
Sell 108 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 3000
|
36 USD |
|
3 years ago
Sep 27, 2021
|
Sell 108 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
36 USD |
|
3 years ago
Sep 22, 2021
|
Sell 2.11 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 58146
|
36.24 USD |
|
3 years ago
Sep 22, 2021
|
Sell 621 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 16854
|
36.83 USD |
|
3 years ago
Sep 20, 2021
|
Sell 1.66 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 48097
|
34.46 USD |
|
3 years ago
Sep 20, 2021
|
Sell 651 K
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 18570
|
35.03 USD |
|
3 years ago
Sep 17, 2021
|
Sell 221 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 6265
|
35.32 USD |
|
3 years ago
Sep 17, 2021
|
Sell 494 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 13735
|
35.96 USD |
|
3 years ago
Sep 13, 2021
|
Sell 399 M
USD
|
EQT Avatar Parent L.P.
10 percent owner
|
- 13394635
|
29.799 USD |
|
3 years ago
Sep 13, 2021
|
Sell 18.5 M
USD
|
SLAINE MASON P
Director
|
- 620668
|
29.799 USD |
|
3 years ago
Sep 09, 2021
|
Sell 202 K
USD
|
Pedersen Leif E
PRESIDENT, SOFTWARE
|
- 6241
|
32.4 USD |
|
3 years ago
Sep 09, 2021
|
Sell 165 K
USD
|
Pedersen Leif E
PRESIDENT, SOFTWARE
|
- 4950
|
33.38 USD |
|
3 years ago
Sep 09, 2021
|
Sell 533 K
USD
|
Pedersen Leif E
PRESIDENT, SOFTWARE
|
- 15447
|
34.5 USD |
|
3 years ago
Sep 09, 2021
|
Sell 849 K
USD
|
Pedersen Leif E
PRESIDENT, SOFTWARE
|
- 24085
|
35.25 USD |
|
3 years ago
Sep 09, 2021
|
Sell 18 K
USD
|
Pedersen Leif E
PRESIDENT, SOFTWARE
|
- 500
|
36.1 USD |
|
3 years ago
Sep 02, 2021
|
Sell 131 K
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 3900
|
33.51 USD |
|
3 years ago
Sep 02, 2021
|
Sell 64.9 K
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 1900
|
34.15 USD |
|
3 years ago
Sep 02, 2021
|
Sell 1.78 M
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 48462
|
36.64 USD |
|
3 years ago
Sep 02, 2021
|
Sell 7.44 K
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 200
|
37.21 USD |
|
3 years ago
Sep 01, 2021
|
Sell 626 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 18554
|
33.76 USD |
|
3 years ago
Sep 01, 2021
|
Sell 27.4 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 800
|
34.24 USD |
|
3 years ago
Sep 01, 2021
|
Sell 653 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 19409
|
33.66 USD |
|
3 years ago
Sep 01, 2021
|
Sell 361 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 10591
|
34.06 USD |
|
3 years ago
Aug 30, 2021
|
Sell 302 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 9000
|
33.5 USD |
|
3 years ago
Aug 25, 2021
|
Sell 755 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 24308
|
31.08 USD |
|
3 years ago
Aug 25, 2021
|
Sell 1.59 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 50692
|
31.37 USD |
|
3 years ago
Aug 24, 2021
|
Sell 225 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 7500
|
30 USD |
|
3 years ago
Aug 19, 2021
|
Sell 354 K
USD
|
Choe Jieun W.
CHIEF STRATEGY & MARKETING
|
- 12500
|
28.34 USD |
|
3 years ago
Aug 16, 2021
|
Sell 229 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 8000
|
28.58 USD |
|
3 years ago
Aug 16, 2021
|
Sell 1.84 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 65267
|
28.21 USD |
|
3 years ago
Aug 16, 2021
|
Sell 40.5 K
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 1400
|
28.9 USD |
|
3 years ago
Aug 16, 2021
|
Sell 143 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 5000
|
28.58 USD |
|
3 years ago
Aug 11, 2021
|
Sell 533 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 19354
|
27.54 USD |
|
3 years ago
Aug 02, 2021
|
Sell 189 M
USD
|
EQT Avatar Parent L.P.
10 percent owner
|
- 7252632
|
26 USD |
|
3 years ago
Jul 28, 2021
|
Sell 1.96 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 75000
|
26.16 USD |
|
3 years ago
Jul 26, 2021
|
Sell 78.8 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
26.27 USD |
|
3 years ago
Jul 19, 2021
|
Sell 1.62 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 66667
|
24.37 USD |
|
3 years ago
Jul 01, 2021
|
Sell 542 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 19354
|
28.03 USD |
|
3 years ago
Jun 28, 2021
|
Sell 85.1 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 3000
|
28.38 USD |
|
3 years ago
Jun 24, 2021
|
Sell 132 K
USD
|
Traynor Richard M.
SVP AND GENERAL COUNSEL
|
- 5000
|
26.37 USD |
|
3 years ago
Jun 23, 2021
|
Sell 1.98 M
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 74800
|
26.53 USD |
|
3 years ago
Jun 23, 2021
|
Sell 5.43 K
USD
|
Feehery William F
CHIEF EXECUTIVE OFFICER
|
- 200
|
27.17 USD |
|
3 years ago
Jun 22, 2021
|
Sell 1.8 M
USD
|
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
|
- 66666
|
26.94 USD |
|
3 years ago
Jun 16, 2021
|
Sell 135 K
USD
|
Edge Justin
PRES., REGULATORY & ACCESS
|
- 5000
|
27.015 USD |
|
3 years ago
Jun 14, 2021
|
Sell 449 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 16347
|
27.49 USD |
|
3 years ago
Jun 14, 2021
|
Sell 84.5 K
USD
|
Aspbury Robert
PRESIDENT, SIMCYP
|
- 3007
|
28.11 USD |
|
3 years ago
Jun 11, 2021
|
Sell 1.6 M
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 62445
|
25.7 USD |
|
3 years ago
Jun 11, 2021
|
Sell 1.18 M
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 46079
|
25.71 USD |
|
3 years ago
Jun 11, 2021
|
Sell 10.6 K
USD
|
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
|
- 400
|
26.59 USD |
|
3 years ago
Mar 29, 2021
|
Sell 209 M
USD
|
EQT Avatar Parent L.P.
10 percent owner
|
- 8674151
|
24.125 USD |
|
4 years ago
Dec 15, 2020
|
Bought
115 K USD
|
WALSH MATTHEW M
Director
|
+ 5000
|
23 USD |
|
4 years ago
Dec 15, 2020
|
Sell 306 M
USD
|
EQT Avatar Parent L.P.
10 percent owner
|
- 14167717
|
21.62 USD |
|
4 years ago
Dec 15, 2020
|
Bought
460 K USD
|
CASHMAN JAMES E III
Director
|
+ 20000
|
23 USD |
|
4 years ago
Dec 15, 2020
|
Bought
506 K USD
|
McLean Stephen M.
Director
|
+ 22000
|
23 USD |
|
4 years ago
Dec 15, 2020
|
Bought
5.64 K USD
|
Traynor Richard M.
SVP and General Counsel
|
+ 245
|
23 USD |
7. News
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.
globenewswire.com
- 2 weeks ago
Cerrado Gold Provides an Update on its Mont Sorcier High Purity 67%+ Iron Grade Project in Quebec
Detailed Metallurgical test work is ongoing and reaffirms production of DRI grade, 67%+ or better iron concentrate with combined Silica and Alumina below 2.5% Work Programs initiated and DRA Global appointed to deliver NI 43-101 Bankable Feasibility Study by end of Q1 2026 2022 PEA on Mont Sorcier provided an NPV8% of US$1.6 Billion for a 21-year mine life producing 5MT of Iron Concentrate per year (300,000 oz/Au equiv.) generating US$348M per annum in cash flow based upon initial capex of US$574M UKEF and TD Bank have agreed to sponsor 70% of project capital required subject to customary conditions of Export Credit Agency funding (All numbers reported in US dollars) TORONTO, ON / ACCESSWIRE / December 4, 2024 / (TSXV:CERT)(OTCQX:CRDOF) ("Cerrado" or the "Company") is pleased to provide an update on its ongoing work programs to complete a NI 43-101 Bankable Feasibility Study("BFS") by end of Q1 2026 on its High Purity, DRI Grade, +67% iron Mont Sorcier magnetite iron ore project located near Chibougamau, Quebec.
accesswire.com
- 1 month ago
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list
globenewswire.com
- 1 month ago
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
seekingalpha.com
- 2 months ago
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago.
zacks.com
- 2 months ago
Certara Reports Third Quarter 2024 Financial Results
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.
globenewswire.com
- 2 months ago
Certara to Participate in the Stephens Annual Investment Conference
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.
globenewswire.com
- 2 months ago
Certara Appoints John Reynders as New Independent Board Member
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
globenewswire.com
- 3 months ago
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
globenewswire.com
- 3 months ago
Certara Completes Acquisition of Chemaxon
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
globenewswire.com
- 3 months ago
Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon
The final trades of the day with the Fast Money traders.
youtube.com
- 3 months ago
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
globenewswire.com
- 4 months ago
8. Profile
Summary
Certara, Inc. CERT
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 1.88 B
Dividend Yield
0.00%
Description
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Contact
100 Overlook Center, Princeton, NJ, 08540
https://www.certara.com
IPO
Date
Dec. 11, 2020
Employees
1338
Officers
Ms. Sheila Rocchio MBA
Chief Marketing Officer
Dr. Frederic Yves Bois
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Dr. Patrick F. Smith Pharm.D.
President of Certara Drug Development Solutions
Mr. Ron DiSantis
Senior Vice President of Corporate Development
Dr. Robert P. Aspbury Ph.D.
President of Certara Scientific Software
Mr. Daniel Corcoran
Chief Counsel
Ms. Rona Anhalt
Chief Human Resources Officer
Mr. Leif E. Pedersen
President & Chief Commercial Officer
Mr. John E. Gallagher III
SVice President, Principal Accounting Officer & Chief Financial Officer
Dr. William F. Feehery Ph.D.
Chief Executive Officer & Director